This article is based on a single Tier-3 source (Wired). The source URL was not independently accessible at the time of preparation. Specific figures, quotes, partnership details, and dates reported by Wired have not been independently verified and are not reproduced here. Per editorial policy §17, this article is limited to claims derivable from the article headline and standfirst only.
Isomorphic Labs, a UK-based biotech company spun out of Alphabet’s Google DeepMind research subsidiary, is preparing to move drug candidates designed using its platform into human clinical trials, according to Wired’s reporting. Wired reports the company’s president, Max Jaderberg, made the announcement at the WIRED Health conference in London in April 2026.
Wired’s reporting indicates the company has partnerships with pharmaceutical firms including Eli Lilly and Novartis. Wired also reports the move into clinical trials is later than the company had previously projected.
Isomorphic Labs uses AlphaFold, a protein structure prediction platform, as the foundation for its drug discovery work. AlphaFold was developed at Google DeepMind; its co-creators, Demis Hassabis and John Jumper, were awarded the Nobel Prize in chemistry in 2024.
Wired did not report a confirmed date for when trial enrollment would begin, according to its reporting.